Current role of multiparametric magnetic resonance imaging for prostate cancer.

Multiparametric magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer, and targeting or guiding prostate biopsy.

mp-MRI consists of T2-weighted imaging (T2WI) combined with several functional sequences including diffusion-weighted imaging (DWI), perfusion or dynamic contrast-enhanced imaging (DCEI) and spectroscopic imaging. Recently, mp-MRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mp-MRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. Because assessment on mp-MRI can be subjective, use of the newly developed standardized reporting Prostate Imaging and Reporting Archiving Data System (PI-RADS) scoring system and education of specialist radiologists are essential for accurate interpretation. This review focuses on the current place of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

Quantitative imaging in medicine and surgery. 2015 Oct [Epub]

Romaric Loffroy, Olivier Chevallier, Morgan Moulin, Sylvain Favelier, Pierre-Yves Genson, Pierre Pottecher, Gilles Crehange, Alexandre Cochet, Luc Cormier

1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France.

PubMed